Your browser doesn't support javascript.
loading
Effects of somatostatin receptor ligands on bone metabolism in acromegaly / 中华内分泌代谢杂志
Chinese Journal of Endocrinology and Metabolism ; (12): 517-521, 2022.
Artículo en Chino | WPRIM | ID: wpr-957583
ABSTRACT

Objective:

To investigate the effect of somatostatin receptor ligands (SRLs) on bone metabolism in patients with acromegaly.

Methods:

Retrospective analysis of clinical data of acromegaly patients( n=100) received surgery or SRLs alone for 3 months. The changes of growth hormone (GH), insulin-like growth factor-1 (IGF-1), osteocalcin (OC), N-mid fragment of osteocalcin (N-MID), amino-terminal peptide of type I procollagen (P1NP) and C-terminal peptide degradation product of type I collagen(CTX) were compared before and after treatment. Patients were divided into drug treatment group and surgical group according to treatment methods. According to the decline of GH after medication, patients in the drug treatment group were further divided into drug sensitive group and drug insensitive group.

Results:

The average dynamic GH and IGF-1 indexes in the drug treatment group were significantly decreased after treatment compared with before treatment (both P<0.05), and CTX was also significantly decreased after treatment [1.25 (0.67, 1.40) ng/mL vs 1.34 (0.57, 1.68) ng/mL, P<0.05]. The mean dynamic GH, IGF-1 index, OC, N-MID, P1NP, and CTX in surgical group were significantly decreased after treatment compared with before treatment (all P<0.01). In the surgical group, there was a positive correlation between GH difference (&Delta;GH) and N-mid difference (&Delta;N-MID; r=0.454, P=0.026), and there was a positive correlation between IGF-1 index difference (&Delta;IGF-1 index) and CTX difference (&Delta;CTX; r=0.339, P=0.036). After treatment, the mean dynamic GH, IGF-1 index, CTX, P1NP, and N-MID in drug treatment group were significantly higher than those in surgical group (all P<0.001). CTX and N-MID decreased significantly after treatment in drug sensitive group compared with drug insensitive group (35.3% vs 7.2%, P<0.001; 24.1% vs 11.8%, P<0.05), and &Delta;GH was positively correlated with &Delta;CTX ( r=0.328, P=0.004).

Conclusion:

SRLs treatment can reduce bone formation marker N-MID and bone resorption marker CTX, improving the high turnover state of bone metabolism in patients with acromegaly, which may attribute to the reduction of GH and IGF-1 levels.

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Idioma: Chino Revista: Chinese Journal of Endocrinology and Metabolism Año: 2022 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Idioma: Chino Revista: Chinese Journal of Endocrinology and Metabolism Año: 2022 Tipo del documento: Artículo